Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study Meeting Abstract
| Authors: | Shah, M. A.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V. T.; Enzinger, P. C.; Ilson, D. H.; Kim, S. S.; Lordick, F.; Shitara, K.; Van Cutsem, E.; Arozullah, A.; Raizer, J. J.; Park, J. W.; Xu, R. H. |
| Abstract Title: | Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900354 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.TPS365 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS365 -- Source: Wos |
